News & Updates

First-line infliximab shows promise in children with moderate-to-severe CD

09 Mar 2021

Use of infliximab in the first line setting appears to yield better results than conventional treatment in children with moderate-to-severe Crohn’s disease (CD), facilitating short-term clinical and endoscopic remission and being associated with a greater likelihood of maintaining clinical remission at week 52 on azathioprine monotherapy, according to a study.

First-line infliximab shows promise in children with moderate-to-severe CD

09 Mar 2021

COVID-19 ground zero boasts low SARS-CoV-2 seroprevalence

09 Mar 2021

Seroprevalence of antibodies against SARS-CoV-2 remains low in Wuhan, China, despite being the site where the novel coronavirus disease (COVID-19) was first detected, a recent study has found.

COVID-19 ground zero boasts low SARS-CoV-2 seroprevalence

09 Mar 2021

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

09 Mar 2021

Netarsudil falls short of reducing the risk of steroid-induced elevation of intraocular pressure (IOP) in patients who have received corneal transplant, a study has found.

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

09 Mar 2021

Layperson empathy phone calls help reduce loneliness, depression and anxiety during COVD-19

09 Mar 2021 by

A layperson-delivered, empathy-oriented telephone call programme reduces loneliness, depression and anxiety compared with no calls, and improves general mental health of the participants within 4 weeks, results of a randomized trial have shown.

Layperson empathy phone calls help reduce loneliness, depression and anxiety during COVD-19

09 Mar 2021

CAR T-cell therapy makes it to the clinic in Hong Kong

09 Mar 2021 by

Haematologists from the University of Hong Kong (HKU) have reported initial success with chimeric antigen receptor (CAR) T-cell therapy, treating the first patient in Hong Kong in May 2020 in a global lymphoma trial and another leukaemia patient in October 2020 in a real-world clinical practice setting.

CAR T-cell therapy makes it to the clinic in Hong Kong

09 Mar 2021

Brief CBT effective for reducing insomnia in at-risk adolescents

09 Mar 2021 by

Results of the world’s first randomized controlled study of a 4-week brief insomnia prevention programme for at-risk adolescents show a 71 percent reduction in the risk of developing insomnia, investigators from the Chinese University of Hong Kong (CUHK) have reported.

Brief CBT effective for reducing insomnia in at-risk adolescents

09 Mar 2021

Neurologic involvement common among children and adolescents with COVID-19

09 Mar 2021 by

A case series of 1,695 children and adolescents hospitalized for coronavirus disease 2019 (COVID-19) finds neurological involvement in 22 percent of patients.

Neurologic involvement common among children and adolescents with COVID-19

09 Mar 2021

Prpf19 a potential new target in hereditary ataxia model

09 Mar 2021 by

Researchers from the Chinese University of Hong Kong (CUHK) have unveiled the involvement of an E3 ligase pre-mRNA processing factor 19 (Prpf19) in spinocerebellar ataxia type 3 (SCA3) pathogenesis and found its interacting partner, exocyst complex component 7 (Exoc7), to have an opposite modulating effect on disease protein ataxin-3 (ATXN3).

Prpf19 a potential new target in hereditary ataxia model

09 Mar 2021

PPI prophylaxis may protect against post-PVI mediastinal complications

08 Mar 2021

Prophylaxis with proton pump inhibitors (PPI) can potentially avert mediastinal lesions associated with pulmonary vein isolation (PVI) among atrial fibrillation patients with pre-existing reflux oesophagitis, a recent study has shown.

PPI prophylaxis may protect against post-PVI mediastinal complications

08 Mar 2021

COVID-19 after-effects evident 3 months after hospital discharge

08 Mar 2021 by

Patients hospitalized for COVID-19 may experience after-effects of the condition 3 months post-discharge, according to a study from The Netherlands.

COVID-19 after-effects evident 3 months after hospital discharge

08 Mar 2021

News & Updates

Filter by Specialty:

Specialty:

First-line infliximab shows promise in children with moderate-to-severe CD

First-line infliximab shows promise in children with moderate-to-severe CD

COVID-19 ground zero boasts low SARS-CoV-2 seroprevalence

COVID-19 ground zero boasts low SARS-CoV-2 seroprevalence

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

Netarsudil no help in steroid-induced IOP elevation after corneal transplantation

Layperson empathy phone calls help reduce loneliness, depression and anxiety during COVD-19

Layperson empathy phone calls help reduce loneliness, depression and anxiety during COVD-19

CAR T-cell therapy makes it to the clinic in Hong Kong

CAR T-cell therapy makes it to the clinic in Hong Kong

Brief CBT effective for reducing insomnia in at-risk adolescents

Brief CBT effective for reducing insomnia in at-risk adolescents

Neurologic involvement common among children and adolescents with COVID-19

Neurologic involvement common among children and adolescents with COVID-19

Prpf19 a potential new target in hereditary ataxia model

Prpf19 a potential new target in hereditary ataxia model

PPI prophylaxis may protect against post-PVI mediastinal complications

PPI prophylaxis may protect against post-PVI mediastinal complications

COVID-19 after-effects evident 3 months after hospital discharge

COVID-19 after-effects evident 3 months after hospital discharge